May 07, 2019 12:43pm EDT Medexus Pharmaceuticals Launches New Metoject® Subcutaneous 15mg Dosage for the Treatment of Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis in Canada
Mar 06, 2019 7:50am EST Medexus Granted Authorization by Health Canada to Distribute Treosulfan in Canada
Feb 25, 2019 4:05pm EST Medexus Pharmaceuticals Announces 512% Increase in Revenue to $14.4 Million for the Third Quarter of Fiscal 2019
Feb 12, 2019 8:00am EST Medexus Lists October 2018 Unsecured Convertible Debentures on the TSX Venture Exchange
Dec 17, 2018 2:30pm EST Medexus Announces New Chief Executive Officer, Chair of the Board of Directors, Other Organizational Updates and Equity Incentive Grants
